Kazia Financial Statements From 2010 to 2026

KZIA Stock  USD 5.34  0.33  6.59%   
Kazia Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Kazia Therapeutics' valuation are provided below:
Gross Profit
1.8 M
Market Capitalization
60.5 M
Enterprise Value Revenue
1.8 K
Revenue
1.8 M
Earnings Share
(13.39)
We have found one hundred twenty available fundamental ratios for Kazia Therapeutics, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of Kazia Therapeutics last-minute market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. As of February 17, 2026, Market Cap is expected to decline to about 11.4 M. In addition to that, Enterprise Value is expected to decline to about 7.1 M

Kazia Therapeutics Total Revenue

35,910

Check Kazia Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kazia Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Interest Expense of 2.3 K or Selling General Administrative of 8.6 M, as well as many indicators such as Price To Sales Ratio of 212, Dividend Yield of 0.0 or Days Sales Outstanding of 669. Kazia financial statements analysis is a perfect complement when working with Kazia Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Kazia Stock
Check out the analysis of Kazia Therapeutics Correlation against competitors.

Kazia Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets5.2 M5.5 M25.2 M
Slightly volatile
Other Current Liabilities9.7 M9.2 M4.7 M
Slightly volatile
Total Current Liabilities17 M16.2 M7.8 M
Slightly volatile
Accounts Payable2.6 M5.1 M2.3 M
Slightly volatile
Cash3.7 M3.9 M12.6 M
Slightly volatile
Non Current Assets Total1.2 M1.3 M10 M
Pretty Stable
Cash And Short Term Investments3.7 M3.9 M12.6 M
Slightly volatile
Net Receivables77 K81 K456.3 K
Slightly volatile
Common Stock Total Equity115.2 M72.3 M108.3 M
Slightly volatile
Common Stock Shares Outstanding1.3 M1.3 M454.7 K
Slightly volatile
Liabilities And Stockholders Equity5.2 M5.5 M25.1 M
Slightly volatile
Total Liabilities11.6 M16.5 M11 M
Slightly volatile
Total Current Assets4.2 M4.4 M15.3 M
Slightly volatile
Intangible Assets1.2 M1.3 M8.4 M
Slightly volatile
Common Stock113.9 M110.7 M119.1 M
Slightly volatile
Capital Stock89.9 M141.5 M64.5 M
Slightly volatile

Kazia Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.2 M1.1 M1.1 M
Slightly volatile
Selling General Administrative8.6 M7.8 M6.1 M
Slightly volatile
Total Revenue35.9 K37.8 K3.2 M
Slightly volatile
Other Operating Expenses21.7 M12.8 M17.2 M
Pretty Stable
Research Development10.7 M8.4 M9.3 M
Slightly volatile
Total Operating Expenses16.8 M12.8 M15 M
Slightly volatile
Selling And Marketing Expenses108.6 K114.3 K504.3 K
Slightly volatile
Interest Income76.7 K64.8 K157.2 K
Slightly volatile
Reconciled Depreciation1.6 M1.1 M1.4 M
Very volatile

Kazia Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow1.4 M1.5 M11.2 M
Pretty Stable
Depreciation1.2 M1.1 M1.1 M
Slightly volatile
End Period Cash Flow3.7 M3.9 M12.3 M
Slightly volatile
Stock Based Compensation716.7 K751 K623.9 K
Pretty Stable
Issuance Of Capital Stock12.8 M17 M8.3 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2122244.9 K
Pretty Stable
Days Sales Outstanding66970425.8 K
Very volatile
Average Payables697.8 K734.6 K1.1 M
Slightly volatile
Stock Based Compensation To Revenue13.2913.99145
Pretty Stable
Capex To Depreciation0.0090.00950.286
Slightly volatile
Inventory Turnover2.081.631.5853
Pretty Stable
Days Of Inventory On Hand337296255
Slightly volatile
Sales General And Administrative To Revenue1781871.1 K
Pretty Stable
Research And Ddevelopement To Revenue1491572.1 K
Pretty Stable
Capex To Revenue0.00110.00120.1067
Slightly volatile
Cash Per Share4.334.56289
Slightly volatile
Intangibles To Total Assets0.260.160.3728
Pretty Stable
Current Ratio0.380.44.6762
Slightly volatile
Receivables Turnover0.40.42244
Very volatile
Capex Per Share0.130.1426.1241
Slightly volatile
Average Receivables240252453.3 K
Slightly volatile
Revenue Per Share0.04190.0441122
Slightly volatile
Interest Debt Per Share0.390.4228.8816
Slightly volatile
Debt To Assets0.06040.05880.0943
Slightly volatile
Graham Number0.750.840.9212
Slightly volatile
Operating Cycle66970425.8 K
Very volatile
Ebt Per Ebit0.791.421.0267
Slightly volatile
Long Term Debt To Capitalization3.0E-43.0E-40.002
Slightly volatile
Quick Ratio0.380.44.5778
Slightly volatile
Cash Ratio0.340.364.2191
Slightly volatile
Cash Conversion Cycle66970425.9 K
Very volatile
Days Of Inventory Outstanding337296255
Slightly volatile
Days Of Sales Outstanding66970425.8 K
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.161.151.0365
Very volatile
Fixed Asset Turnover16.3711.820.3899
Slightly volatile
Debt Ratio0.06040.05880.0943
Slightly volatile
Price Sales Ratio2122244.9 K
Pretty Stable
Asset Turnover0.00760.0080.0952
Slightly volatile

Kazia Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap11.4 M12 M33.3 M
Pretty Stable

Kazia Fundamental Market Drivers

Kazia Upcoming Events

4th of January 2024
Upcoming Quarterly Report
View
30th of September 2023
Next Fiscal Quarter End
View
29th of August 2024
Next Fiscal Year End
View
30th of June 2023
Last Quarter Report
View
30th of June 2023
Last Financial Announcement
View

About Kazia Therapeutics Financial Statements

Kazia Therapeutics stakeholders use historical fundamental indicators, such as Kazia Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Kazia Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Kazia Therapeutics' assets and liabilities are reflected in the revenues and expenses on Kazia Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Kazia Therapeutics Ltd. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-1.6 M-1.5 M
Total Revenue37.8 K35.9 K
Stock Based Compensation To Revenue 13.99  13.29 
Sales General And Administrative To Revenue 186.86  177.51 
Research And Ddevelopement To Revenue 156.99  149.14 
Revenue Per Share 0.04  0.04 
Ebit Per Revenue(389.27)(408.74)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Kazia Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kazia Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kazia Therapeutics Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kazia Therapeutics Ltd Stock:
Check out the analysis of Kazia Therapeutics Correlation against competitors.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kazia Therapeutics. Expected growth trajectory for Kazia significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Kazia Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(13.39)
Revenue Per Share
1.669
Quarterly Revenue Growth
(0.27)
Return On Assets
(0.64)
Return On Equity
(38.92)
Kazia Therapeutics's market price often diverges from its book value, the accounting figure shown on Kazia's balance sheet. Smart investors calculate Kazia Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Kazia Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Kazia Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Kazia Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Kazia Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.